Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human Siglec-9 Biotinylated Antibody, R&D Systems™

Goat Polyclonal Antibody
Supplier: R&D Systems BAF1139
This item is not returnable.
View return policy
Description
Siglec-9 Polyclonal specifically detects Siglec-9 in Human samples. It is validated for Western Blot, Flow Cytometry, Immunocytochemistry, ELISA Detection (Matched Antibody Pair).Specifications
Siglec-9 | |
Polyclonal | |
Biotin | |
Q9Y336 | |
SIGLEC9 | |
Mouse myeloma cell line NS0-derived recombinant human Siglec-9 Gln18-Gly348 Accession # Q9Y336 | |
50 μg | |
Primary | |
Detects human Siglec-9 in direct ELISAs and Western blots. In direct ELISAs, less than 0.2% cross-reactivity with recombinant human (rh) Siglec-2, rhSiglec-3, rhSiglec-5, rhSiglec-7, and rhSiglec-10 is observed. In Western blots, approximately 25% cross-reactivity with rhSiglec-7 is observed, approximately 5% cross-reactivity with rhSiglec-3 and rhSiglec-5 is observed, and less than 1% cross-reactivity with rhSiglec-2 is observed. | |
Human | |
IgG |
Western Blot, Flow Cytometry, Immunocytochemistry, ELISA | |
LYOPH | |
Western Blot 0.1 ug/mL, Flow Cytometry 0.25 ug/10^6 cells, Immunocytochemistry 5-15 ug/mL, ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL | |
CD329, CDw329, FOAP-9, OBBP-Like, Protein FOAP-9, sialic acid binding Ig-like lectin 9, sialic acid-binding Ig-like lectin 9, siglec-9, Siglec9 | |
Goat | |
Affinity Purified | |
RUO | |
27180 | |
Reconstitute at 0.2 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction